# Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude

Study · id `cardio:ct-nct04915365` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04915365](<https://clinicaltrials.gov/study/NCT04915365>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04915365

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04915365. Randomized; no masking; primary purpose prevention. Start 2021-05-01 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04915365, source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)
- Started: 2021-05-01 (actual) (ClinicalTrials.gov record NCT04915365, source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04915365, source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT04915365, source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)
- Countries: Kyrgyzstan (ClinicalTrials.gov record NCT04915365, source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04915365-2022-11-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude
- Condition: Right Heart Function
- Condition: Chronic Obstructive Pulmonary Disease
- Condition: Altitude Sickness
- Intervention (Drug): Acetazolamide
- Intervention (Drug): Placebo
- Lead sponsor: University of Zurich
- Lead sponsor class: OTHER
- Collaborator: National Center of Cardiology and Internal Medicine, Kyrgyz Republic
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: University of Zurich (`cardio:org-university-of-zurich`)

## Provenance

Content hash: e640f7acf5d92c3672525bc04ae949d99c05f760755c4812d658bc8d3d837aec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
